Keryx Biopharmaceuticals Inc fka KERX

[califax]

Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference

Date : 03/10/2010 @ 8:30AM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals (MM) (KERX)

http://ih.advfn.com/p.php?pid=nmona&article=41909237&symbol=KERX

NEW YORK, March 10 /PRNewswire-FirstCall/ --

Keryx Biopharmaceuticals, Inc. today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 22nd Annual ROTH OC Growth Stock Conference, being held in Laguna Niguel, CA. Mr. Bentsur's presentation will take place on Tuesday March 16, 2010 at 8:00 a.m. PT (11:00 am ET).

A live webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com/. An archived version of the webcast will be available following the conclusion of the live presentation.

As previously announced, the Company will also be presenting at the Cowen and Company 30th Annual Health Care Conference, taking place at The Boston Marriott Copley Place Hotel in Boston, MA. A live webcast of Mr. Bentsur's presentation, which will take place tomorrow, Thursday, March 11, 2010 at 11:05 a.m. ET, will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com/.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK pathway, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in a Phase 3 trial, under Special Protocol Assessment (SPA), in multiple myeloma, with a Phase 3 trial in refractory metastatic colorectal cancer, under SPA, pending commencement, and in Phase 2 clinical development for several other tumor types. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is pending commencement under an SPA agreement with the FDA. Keryx is headquartered in New York City.

Media Contact: Lauren Fischer, Director of Investor Relations, Keryx Biopharmaceuticals, [phone], [e-mail]

DATASOURCE: Keryx Biopharmaceuticals, Inc.

CONTACT: Lauren Fischer, Director of Investor Relations, KeryxBiopharmaceuticals, [phone], [e-mail]

Web Site: http://investors.keryx.com/